NASDAQ:AFMD - Affimed Stock Price, Forecast & News

Affimed trades on the NASDAQ under the ticker symbol "AFMD."

Affimed NV (NASDAQ:AFMD) issued its earnings results on Tuesday, November, 19th. The biopharmaceutical company reported ($0.19) EPS for the quarter, missing the Zacks' consensus estimate of ($0.14) by $0.05. The biopharmaceutical company earned $2.34 million during the quarter, compared to analyst estimates of $6.77 million. Affimed had a negative net margin of 25.43% and a negative return on equity of 29.52%. View Affimed's Earnings History.

Affimed is scheduled to release their next quarterly earnings announcement on Wednesday, March 25th 2020. View Earnings Estimates for Affimed.

3 brokerages have issued 1 year target prices for Affimed's shares. Their forecasts range from $4.17 to $10.00. On average, they expect Affimed's share price to reach $7.39 in the next year. This suggests a possible upside of 217.2% from the stock's current price. View Analyst Price Targets for Affimed.

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Affimed in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Affimed.

News headlines about AFMD stock have trended somewhat negative this week, InfoTrie Sentiment Analysis reports. The research firm scores the sentiment of news coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Affimed earned a media sentiment score of -1.7 on InfoTrie's scale. They also gave news articles about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the company's share price in the near term. View News Stories for Affimed.

Some companies that are related to Affimed include Arcus Biosciences (RCUS), G1 Therapeutics (GTHX), ImmunoGen (IMGN), Vectura Group (VEGPF), Eagle Pharmaceuticals (EGRX), Basilea Pharmaceutica (BPMUF), Cara Therapeutics (CARA), Akero Therapeutics (AKRO), Retrophin (RTRX), Flexion Therapeutics (FLXN), RAPT Therapeutics (RAPT), Molecular Templates (MTEM), Urogen Pharma (URGN), Vanda Pharmaceuticals (VNDA) and Atreca (BCEL).

Based on aggregate information from My MarketBeat watchlists, some companies that other Affimed investors own include JetBlue Airways (JBLU), Novavax (NVAX), Sprint (S), American International Group (AIG), Viking Therapeutics (VKTX), Amarin (AMRN), Catalyst Pharmaceuticals (CPRX), Lipocine (LPCN), Achillion Pharmaceuticals (ACHN) and AcelRx Pharmaceuticals (ACRX).

Affimed's stock is owned by many different of retail and institutional investors. Top institutional shareholders include NEA Management Company LLC (8.04%), Acadian Asset Management LLC (4.03%), Point72 Asset Management L.P. (2.23%), State Street Corp (1.46%), AQR Capital Management LLC (1.39%) and Geode Capital Management LLC (0.87%).

AFMD stock was sold by a variety of institutional investors in the last quarter, including Goldman Sachs Group Inc., Oxford Asset Management LLP, Russell Investments Group Ltd., Virtu Financial LLC and California Public Employees Retirement System.

AFMD stock was acquired by a variety of institutional investors in the last quarter, including Acadian Asset Management LLC, Point72 Asset Management L.P., NEA Management Company LLC, Alpine Global Management LLC, AQR Capital Management LLC, Geode Capital Management LLC, Strs Ohio and Barclays PLC.

Shares of AFMD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of AFMD stock can currently be purchased for approximately $2.33.

Affimed has a market capitalization of $177.64 million and generates $28.03 million in revenue each year. The biopharmaceutical company earns $-23,000,000.00 in net income (profit) each year or ($0.38) on an earnings per share basis. Affimed employs 8,406 workers across the globe.View Additional Information About Affimed.

The official website for Affimed is http://www.affimed.com/.

Affimed's mailing address is IM NEUENHEIMER FELD 582, HEIDELBERG 2M, 69120. The biopharmaceutical company can be reached via phone at 49-62-2167-4360 or via email at [email protected]